Illumina, Inc. (NASDAQ:ILMN) today announced that it is significantly reducing the price for sequencing whole human genomes through the Illumina Genome Network (IGN). The new list price for the service is $5,000 per genome for projects of ten samples or more, and $4,000 for projects of fifty samples or more. IGN is a global service partnership designed to link researchers interested in conducting large-scale whole human genome sequencing projects with leading institutions that can perform such projects using Illumina sequencers.
"We have been very pleased with the success of IGN since its introduction and with how well it has been received by the community," said Christian Henry, Senior Vice President and General Manager, Life Sciences, at Illumina. "Researchers around the world value the rapid turnaround times, high data quality and accessible price points. Recent advancements in HiSeq technology push that value even further and demonstrate our commitment to continuing to lower cost and drive scale through sequencing technology advancements."
Since its introduction in July 2010, IGN has received orders for more than 1,000 samples from a range of academic and commercial institutions. Illumina's sequencers provide data with the industry's most comprehensive list of variants, the most complete alignment and the fewest gaps. IGN has delivered high-quality data with expert project management to customers across the globe. It is expected that the latest pricing will enable existing and prospective customers to expand their study sizes, increase the depth of sequencing coverage especially for tumor samples, and drive further adoption of whole-genome sequencing as the preferred method for assessing variation across genomes.
Source: Illumina
Equipment for single-cell genomics launched by Illumina and Bio-Rad